Skip to main content
PMC home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 1999 Jun;49(443):451–453.

Long-term prescribing of proton pump inhibitors in general practice.

A P Hungin 1, G P Rubin 1, H O'Flanagan 1
PMCID: PMC1313442  PMID: 10562744

Abstract

BACKGROUND: Proton pump inhibitors (PPIs) constitute the largest sector of the National Health Service (NHS) community drugs bill (238 m Pounds; 5.6%). Little is known of the long-term prescribing component of this. AIM: To study the extent, the reasons for, and the cost implications of the long-term prescription of PPIs in general practice. METHOD: Subjects on long-term therapy were identified by searches of computerized and paper records from three practices, comprising 21 GPs with 46,650 patients, representing a population cross section in north-east England. RESULTS: Two hundred and nine (0.45%) patients were on long-term PPIs (range between practices = 0.3% to 0.55%): 87% were on omeprazole, 13% lansoprazole; average age = 60 years (male = 56 years, female = 64 years; range = 14 to 91 years); male to female ratio = 47:53. The main indications were 'reflux' (39%), 'oesophagitis' (17%), non-specified 'dyspepsia' (24%), 'peptic ulcer' (8%). During the study year, 1952 prescriptions (28-day courses) were issued: a mean of nine per patient (range = 1 to 8). Sixteen per cent of patients requested fewer than six prescriptions, 27% requested between six and nine prescriptions, and only 21% requested sufficient prescriptions for the entire year. The average cost was 3707 Pounds per general practitioner per annum, or 320,000 Pounds for the district, representing 40% of the total PPI bill. CONCLUSION: Of the total population, 0.45% were prescribed long-term PPIs; most for symptom relief. The long-term component comprised 40% of all PPI costs estimated at 100 million Pounds per annum for the United Kingdom. Most patients took their treatment only intermittently. More research is needed into strategies for rationalization of long-term PPI therapy. For most patients, doctors can advise on-demand rather than regular once-daily therapy.

Full Text

The Full Text of this article is available as a PDF (41.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buetow S. A., Sibbald B., Cantrill J. A., Halliwell S. Prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom, 1980-95: systematic literature review. BMJ. 1996 Nov 30;313(7069):1371–1374. doi: 10.1136/bmj.313.7069.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dehn T. C., Shepherd H. A., Colin-Jones D., Kettlewell M. G., Carroll N. J. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut. 1990 May;31(5):509–513. doi: 10.1136/gut.31.5.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Heading R. C. Long-term management of gastroesophageal reflux disease. Scand J Gastroenterol Suppl. 1995;213:25–30. [PubMed] [Google Scholar]
  4. Hungin A. P., Thomas P. R., Bramble M. G., Corbett W. A., Idle N., Contractor B. R., Berridge D. C., Cann G. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract. 1994 Nov;44(388):519–521. [PMC free article] [PubMed] [Google Scholar]
  5. Johannessen T., Petersen H., Kristensen P., Fosstvedt D., Kleveland P. M., Dybdahl J., Løge I. Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials. Scand J Gastroenterol. 1992;27(3):189–195. doi: 10.3109/00365529208999947. [DOI] [PubMed] [Google Scholar]
  6. Kuipers E. J., Lundell L., Klinkenberg-Knol E. C., Havu N., Festen H. P., Liedman B., Lamers C. B., Jansen J. B., Dalenback J., Snel P. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996 Apr 18;334(16):1018–1022. doi: 10.1056/NEJM199604183341603. [DOI] [PubMed] [Google Scholar]
  7. Kuster E., Ros E., Toledo-Pimentel V., Pujol A., Bordas J. M., Grande L., Pera C. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994 Jan;35(1):8–14. doi: 10.1136/gut.35.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Richter J. E. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med. 1992 Mar 19;326(12):825–827. doi: 10.1056/NEJM199203193261209. [DOI] [PubMed] [Google Scholar]
  9. Rubin G. P., Contractor B., Bramble M. G. The use of long-term acid-suppression therapy. Br J Clin Pract. 1995 May-Jun;49(3):119–120. [PubMed] [Google Scholar]
  10. Sandmark S., Carlsson R., Fausa O., Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988 Jun;23(5):625–632. doi: 10.3109/00365528809093923. [DOI] [PubMed] [Google Scholar]
  11. Schindlbeck N. E., Klauser A. G., Berghammer G., Londong W., Müller-Lissner S. A. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992 Aug;33(8):1016–1019. doi: 10.1136/gut.33.8.1016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Zermansky A. G. Who controls repeats? Br J Gen Pract. 1996 Nov;46(412):643–647. [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES